Danaher Co. (NYSE:DHR) Holdings Raised by Autumn Glory Partners LLC

Autumn Glory Partners LLC grew its stake in shares of Danaher Co. (NYSE:DHR) by 108.2% during the 3rd quarter, HoldingsChannel reports. The fund owned 2,748 shares of the conglomerate’s stock after acquiring an additional 1,428 shares during the period. Autumn Glory Partners LLC’s holdings in Danaher were worth $768,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Good Life Advisors LLC acquired a new position in Danaher in the 3rd quarter worth about $217,000. Oak Thistle LLC bought a new position in Danaher during the second quarter valued at approximately $363,000. Norden Group LLC acquired a new stake in Danaher in the first quarter valued at approximately $4,151,000. Duality Advisers LP bought a new stake in Danaher in the first quarter worth approximately $5,573,000. Finally, Diversified Trust Co increased its stake in shares of Danaher by 75.4% during the 2nd quarter. Diversified Trust Co now owns 4,360 shares of the conglomerate’s stock worth $1,090,000 after purchasing an additional 1,874 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Down 0.5 %

DHR stock opened at $244.12 on Tuesday. The business’s 50-day simple moving average is $268.98 and its 200 day simple moving average is $260.53. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The company has a market cap of $180.82 billion, a PE ratio of 41.38, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the company posted $2.02 earnings per share. Danaher’s revenue was up 3.1% on a year-over-year basis. On average, research analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were given a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on DHR. TD Cowen upped their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Stephens reiterated an “overweight” rating and set a $315.00 price target on shares of Danaher in a research note on Wednesday, October 23rd. The Goldman Sachs Group raised their price objective on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. KeyCorp increased their price target on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Finally, Robert W. Baird reduced their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $287.28.

Insider Activity at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Linda Filler sold 3,928 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.50, for a total value of $1,097,876.00. Following the completion of the sale, the director now owns 41,149 shares in the company, valued at $11,501,145.50. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,059 shares of company stock valued at $8,400,897 over the last quarter. 11.10% of the stock is owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.